December 4, 2014

Ferring Pharmaceuticals Announces Grand Opening of U.S. Operations Center

New facility underscores long-term commitment to the U.S. and to New Jersey

Parsippany, NJ, USA, 4 December 2014 – Ferring Pharmaceuticals has expanded its footprint in New Jersey with the opening of its new U.S. Operations Center on a 25-acre lot located at 100 Interpace Parkway in Parsippany. Instead of relocating or outsourcing manufacturing to other states or overseas, Ferring’s new center is a sign of the company’s continued commitment to New Jersey and bringing new jobs to the local community.

The facility recently completed the integration of staff into the state-of-the-art manufacturing suite and product development laboratories. The U.S. Operations Center will house 275 employees across management, administration, commercial operations, manufacturing and R&D, a set up designed to allow unique opportunities for collaboration across various operational disciplines. Ferring plans to expand that number significantly as the manufacturing facility gradually comes online over the course of the next 18 to 24 months.

“This is just the start of an exciting journey of growth to come,” said Michel Pettigrew, CEO, Ferring Holding Inc. and President of the Executive Board and Chief Operating Officer, Ferring Group. “We hope this new operations center stands as a symbol of our philosophy as a company – a place where our commitment to the science and to our patients is front and center; a learning environment where employees are encouraged to take initiative and stretch beyond their designated role; and a cornerstone of the community, dedicated to giving back.”

The facility allows the company to reinforce its commitment to New Jersey at a time when many pharmaceutical companies are making out-of-state moves. The approach is an example of Ferring’s dedication to the community it serves. Moreover, the move to stay in state provides access to experienced pharmaceutical talent and world class academic institutions. Notably, Ferring is also working with several organizations in New Jersey to offer open positions to veterans of the U.S. armed forces.

“This grand opening serves as a reminder of our commitment to the U.S., New Jersey and to our long-term view on the science that can make a real difference in the lives of the patients we serve,” said Aaron Graff, President and COO Ferring Pharmaceuticals Inc. “As I watch our teams start to integrate into the new operations center, I already see the positive impact the space has on our ability to collaborate across functions within the organization and provide a premium workspace for our employees.”

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a member of the Ferring Pharmaceuticals group, a privately owned, international pharmaceutical group. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464); visit

© 2014 Ferring B.V.
Image: Maggie McGill Photography

Media Contact:
Christy Maginn
P: 202.530.4730

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000062